18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study
Abstract Background Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, 18F-fluoro-deoxy-glucose (18F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of 68Ga-somatostatin analogs. The aim of our study was to evaluate and comp...
Main Authors: | Silvia Taralli, Martina Sollini, Michele Milella, Germano Perotti, Angelina Filice, Massimo Menga, Annibale Versari, Vittoria Rufini |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-07-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13550-018-0423-3 |
Similar Items
-
Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case Report
by: Michele Guida, et al.
Published: (2020-07-01) -
Role of Combined [<sup>68</sup>Ga]Ga-DOTA-SST Analogues and [<sup>18</sup>F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
by: Luciano Carideo, et al.
Published: (2019-07-01) -
Positron Emission Tomography in Merkel Cell Carcinoma
by: Christos Sachpekidis, et al.
Published: (2020-10-01) -
Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
by: Martin H. Cherk, et al.
Published: (2018-01-01) -
A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
by: Rosalba Mansi, et al.
Published: (2020-08-01)